Cargando…

In silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer

BACKGROUND: Abnormal glucose and lipid metabolism plays a critical role in gastric carcinogenesis and development. Hence, we presented a systematic analysis of glucose and lipid metabolism-related genes to explore their function and prognostic value in gastric cancer (GC). METHODS: The consensus clu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yuan, Chen, Zhaofeng, Zhou, Lingshan, Wu, Guozhi, Ma, Xiaomei, Zheng, Ya, Liu, Min, Wang, Yuping, Ji, Rui, Guo, Qinghong, Zhou, Yongning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372230/
https://www.ncbi.nlm.nih.gov/pubmed/35966316
http://dx.doi.org/10.21037/tcr-22-168
_version_ 1784767333966807040
author Yang, Yuan
Chen, Zhaofeng
Zhou, Lingshan
Wu, Guozhi
Ma, Xiaomei
Zheng, Ya
Liu, Min
Wang, Yuping
Ji, Rui
Guo, Qinghong
Zhou, Yongning
author_facet Yang, Yuan
Chen, Zhaofeng
Zhou, Lingshan
Wu, Guozhi
Ma, Xiaomei
Zheng, Ya
Liu, Min
Wang, Yuping
Ji, Rui
Guo, Qinghong
Zhou, Yongning
author_sort Yang, Yuan
collection PubMed
description BACKGROUND: Abnormal glucose and lipid metabolism plays a critical role in gastric carcinogenesis and development. Hence, we presented a systematic analysis of glucose and lipid metabolism-related genes to explore their function and prognostic value in gastric cancer (GC). METHODS: The consensus clustering algorithm was used to identify the molecular subtypes based on glucose and lipid metabolism-related genes. Subsequently, cox regression analysis and lasso regression analysis were utilized to establish a risk prediction model. A clinical nomogram was constructed to assist prognosis assessment. In addition, ESTIMATE and single-sample gene set enrichment analysis (ssGSEA) algorithms were performed to evaluate the immune infiltration of the metabolic model, and GSEA was used for enrichment analysis of the metabolic signature. Finally, we explored the association between the risk model and anti-cancer therapy for the purpose of clinical application for GC treatment. RESULTS: GC samples were divided into 2 subtypes based on glucose and lipid metabolism-related genes, patients in cluster 2 had a better overall survival (OS) than those in cluster 1. Fifty-two genes were identified by univariable regression analysis. Finally, a 13-gene metabolic signature (CACNA1H, CHST1, IGFBP3, NASP, STC1, VCAN, NUP205, NUP43, PGM2L1, CAV1, ELOVL4, PRKAA2, TNFAIP8L3) was successfully constructed that demonstrated good performance in different datasets, as well as an independent hazardous factor for prognosis. In addition, the nomogram constructed with the clinical variables showed higher predictive efficacy for predicting the 1-, 3-, and 5-year OS. The 13-gene metabolic signature was significantly associated with immune scores and immune cell infiltration in high-risk group. Moreover, GSEA analysis revealed that cancer- and immune-related pathways were enriched in the high-risk group. Finally, our results indicated that there might exist an immunosuppressive status in the high-risk groups. CONCLUSIONS: This study demonstrated that glucose and lipid metabolism-related genes were significantly associated with prognosis. Meanwhile, it will provide novel insights into exploring the immunoregulation roles of these genes.
format Online
Article
Text
id pubmed-9372230
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-93722302022-08-13 In silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer Yang, Yuan Chen, Zhaofeng Zhou, Lingshan Wu, Guozhi Ma, Xiaomei Zheng, Ya Liu, Min Wang, Yuping Ji, Rui Guo, Qinghong Zhou, Yongning Transl Cancer Res Original Article BACKGROUND: Abnormal glucose and lipid metabolism plays a critical role in gastric carcinogenesis and development. Hence, we presented a systematic analysis of glucose and lipid metabolism-related genes to explore their function and prognostic value in gastric cancer (GC). METHODS: The consensus clustering algorithm was used to identify the molecular subtypes based on glucose and lipid metabolism-related genes. Subsequently, cox regression analysis and lasso regression analysis were utilized to establish a risk prediction model. A clinical nomogram was constructed to assist prognosis assessment. In addition, ESTIMATE and single-sample gene set enrichment analysis (ssGSEA) algorithms were performed to evaluate the immune infiltration of the metabolic model, and GSEA was used for enrichment analysis of the metabolic signature. Finally, we explored the association between the risk model and anti-cancer therapy for the purpose of clinical application for GC treatment. RESULTS: GC samples were divided into 2 subtypes based on glucose and lipid metabolism-related genes, patients in cluster 2 had a better overall survival (OS) than those in cluster 1. Fifty-two genes were identified by univariable regression analysis. Finally, a 13-gene metabolic signature (CACNA1H, CHST1, IGFBP3, NASP, STC1, VCAN, NUP205, NUP43, PGM2L1, CAV1, ELOVL4, PRKAA2, TNFAIP8L3) was successfully constructed that demonstrated good performance in different datasets, as well as an independent hazardous factor for prognosis. In addition, the nomogram constructed with the clinical variables showed higher predictive efficacy for predicting the 1-, 3-, and 5-year OS. The 13-gene metabolic signature was significantly associated with immune scores and immune cell infiltration in high-risk group. Moreover, GSEA analysis revealed that cancer- and immune-related pathways were enriched in the high-risk group. Finally, our results indicated that there might exist an immunosuppressive status in the high-risk groups. CONCLUSIONS: This study demonstrated that glucose and lipid metabolism-related genes were significantly associated with prognosis. Meanwhile, it will provide novel insights into exploring the immunoregulation roles of these genes. AME Publishing Company 2022-07 /pmc/articles/PMC9372230/ /pubmed/35966316 http://dx.doi.org/10.21037/tcr-22-168 Text en 2022 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Yang, Yuan
Chen, Zhaofeng
Zhou, Lingshan
Wu, Guozhi
Ma, Xiaomei
Zheng, Ya
Liu, Min
Wang, Yuping
Ji, Rui
Guo, Qinghong
Zhou, Yongning
In silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer
title In silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer
title_full In silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer
title_fullStr In silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer
title_full_unstemmed In silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer
title_short In silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer
title_sort in silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372230/
https://www.ncbi.nlm.nih.gov/pubmed/35966316
http://dx.doi.org/10.21037/tcr-22-168
work_keys_str_mv AT yangyuan insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer
AT chenzhaofeng insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer
AT zhoulingshan insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer
AT wuguozhi insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer
AT maxiaomei insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer
AT zhengya insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer
AT liumin insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer
AT wangyuping insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer
AT jirui insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer
AT guoqinghong insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer
AT zhouyongning insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer